- Psychemedics shares dropped substantially after its future revenues from Brazil were put into doubt.
- The company offers a superior method for drug testing that could still see substantial growth as more corporations learn of the benefits.
- The company, with 68% of revenues coming from the U.S., has limited international exposure outside of Brazil, which leaves plenty of room to expand globally.
- Weighing the risks and growth potential, along with the current depressed valuation, resulted in the company being added to our speculative buy list.
Read the Full SeekingAlpha Article HERE
